Metabolic dysfunction-associated steatohepatitis+1
Not recruitingStudy on the Effectiveness of NNC0194-0499 and Semaglutide in Treating Non-Alcoholic Steatohepatitis (NASH) in Patients with Fibrosis Stages 2-4
Study on the Effectiveness of NNC0194-0499 and Semaglutide in Treating Non-Alcoholic Steatohepatitis (NASH) in Patients with Fibrosis Stages 2-4
- Disease:Metabolic dysfunction-associated steatohepatitisNon-alcoholic steatohepatitis
- Substances:CagrilintideNnc0194-0499+1
Belgium- Participants:18–64 years · 65+ years
- Substances:Cagrilintide












